BuSpar generic market development?
Executive Summary
Sales of Bristol-Myers Squibb anxiolytic BuSpar (buspirone) increased 51% in the U.S. for the quarter to $186 mil. Generic competition is expected following the expiration of pediatric exclusivity Nov. 22. "Until then, you will continue to see us advertise this brand directly and drive as much demand as we can," Bristol Worldwide Medicines President Richard Lane said
Sales of Bristol-Myers Squibb anxiolytic BuSpar (buspirone) increased 51% in the U.S. for the quarter to $186 mil. Generic competition is expected following the expiration of pediatric exclusivity Nov. 22. "Until then, you will continue to see us advertise this brand directly and drive as much demand as we can," Bristol Worldwide Medicines President Richard Lane said. |